Davis company working on breathable medicine to aid Covid-19 recovery
A Davis biopharmaceutical startup has licensed a breathable statin technology from the University of California Davis that may help people suffer less and recover faster from Covid-19.
InVixa Inc. plans to be in preclinical trials starting this year for its breathable medicine, which gets into the nose and lungs more quickly than a pill and could treat the respiratory problems caused by viruses and specifically Covid-19. Human trials could begin this year.
“Our initial focus will be to treat…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Mark Anderson Source Type: news
More News: Cholesterol | COVID-19 | Health Management | Pharmaceuticals | Respiratory Medicine | Statin Therapy